Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects

Objective: Bococizumab, a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9, has been shown to reduce low-density lipoprotein cholesterol (LDL-C). Here, we describe the pharmacokinetics and pharmacodynamics of bococizumab and its effect on lipoprotein particle composition a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokote, Koutaro, Suzuki, Akiyuki, Li, Yinhua, Matsuoka, Nobushige, Teramoto, Tamio 
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862531/
https://www.ncbi.nlm.nih.gov/pubmed/31549625
http://dx.doi.org/10.5414/CP203418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862531/
https://www.ncbi.nlm.nih.gov/pubmed/31549625
http://dx.doi.org/10.5414/CP203418

Ejemplares similares